About this item:

715 Views | 601 Downloads

Author Notes:

J-LV has no conflicts of interest related to this article.

JW is a member of the Advisory Boards and an invited speaker for Baxter, Danone, Fresenius-Kabi, Grifols, and Nestlé.


Research Funding:

This report was sponsored by an unrestricted educational grant from Grifols SA (Barcelona, Spain). Grifols had no input into the contents of the text or the decision to publish.

JAR reports patents owned by the University of British Columbia that are related to the genetics of sepsis and its treatment; the University of British Columbia has also submitted a patent related to the use of vasopressin in septic shock. JAR is an inventor on these patents. JAR also reports receiving consulting fees from Ferring Pharmaceuticals (which manufactures vasopressin and is developing selepressin), Grifols (which sells albumin), Trius Pharmaceuticals (which is developing antibiotics), and Sirius Genomics Inc.; and reports having received grant support from Sirius Genomics, Ferring Pharmaceuticals, and Astra Zeneca that is provided to and administered by the University of British Columbia.

MJ has held lectures for B. Braun, Fresenius Kabi, Serumwerk Bernburg, Baxter and Grifols; has received unrestricted research grants from Fresenius Kabi, CSL Behring, Serumwerk Bernburg and Grifols; and is a member of the Grifols AAB.

GM serves on advisory boards for Grifols and CSL Behring, and his institution has received research grant support from Baxter Healthcare.

BG has received honoraria for lectures from Fresenius Kabi and LFB, and he is on the advisory board of Grifols and Fresenius Kabi.

RFR has received honoraria for lectures from Pfizer, Astellas and Grupo Ferrer, and is on the Advisory boards of Grifols, Bellco and Grupo Ferrer.

SAM has received speaker's honoraria from Fresenius Kabi. LG is on the Advisory board of Grifols and has received speaker’s honoraria from KCI, B. Braun, Baxter, Grifols, and Kedrion.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Critical Care Medicine
  • General & Internal Medicine

Albumin administration in the acutely ill: what is new and where next?


Journal Title:

Critical Care


Volume 18, Number 4


, Pages 231-231

Type of Work:

Article | Final Publisher PDF


Albumin solutions have been used worldwide for the treatment of critically ill patients since they became commercially available in the 1940s. However, their use has become the subject of criticism and debate in more recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which groups of patients are most likely to benefit from their use. However, many questions remain related to where exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill patients. © 2014 Vincent et al.; licensee BioMed Central Ltd.

Copyright information:

© 2014 Vincent et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits distribution, public display, and publicly performance, making multiple copies, distribution of derivative works, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact.

Creative Commons License

Export to EndNote